PROPOSED MERGER—YOUR VOTE IS VERY IMPORTANTProposed Merger • June 10th, 2021
Cleveland BioLabs, Inc., a Delaware corporation, or Cleveland BioLabs, and Cytocom Inc., a Delaware corporation, or Cytocom, entered into an Agreement and Plan of Merger, or the Merger Agreement, on October 16, 2020, pursuant to which High Street Acquisition Corp., a direct, wholly owned subsidiary of Cleveland BioLabs, or Merger Sub, will merge with and into Cytocom, with Cytocom surviving as a wholly owned subsidiary of Cleveland BioLabs, and the surviving corporation of the merger, which transaction is referred to herein as the merger. We refer to Cleveland BioLabs immediately following the merger as the combined company.
PROPOSED MERGERProposed Merger • February 9th, 2021
To the stockholders of NTN Buzztime, Inc. and the beneficial holders of the Class A membership interests of Brooklyn ImmunoTherapeutics LLC:
PROPOSED MERGERProposed Merger • April 12th, 2022
On February 22, 2022, Nukkleus Inc., which is referred to as “Nukkleus,” and Brilliant Acquisition Corporation, which is referred to as “Brilliant,” entered into an Agreement and Plan of Merger, as amended and restated on June 23, 2023, as amended by the First Amendment to the Amended and Restated Agreement and Plan of Merger on November 1, 2023, and as it may be further amended from time to time, which is referred to as the “Merger Agreement,” pursuant to which they agreed to combine their respective businesses. Pursuant to the terms of the Merger Agreement, Brilliant will continue out of the British Virgin Islands and into the State of Delaware so as to re-domicile as and become a Delaware corporation (the “Domestication”), following which, BRIL Merger Sub, Inc., a wholly-owned subsidiary of Brilliant and a party to the Merger Agreement, will merge with and into Nukkleus, with Nukkleus surviving the merger as a wholly-owned subsidiary of Brilliant (the “Merger”), such transactions be
PROPOSED MERGER—YOUR VOTE IS VERY IMPORTANTProposed Merger • November 19th, 2008
Kratos Defense & Security Solutions, Inc., or Kratos, and Digital Fusion, Inc., or Digital Fusion, have entered into a merger agreement pursuant to which a wholly owned subsidiary of Kratos will merge with and into Digital Fusion, with Digital Fusion continuing as a wholly owned subsidiary of Kratos. Kratos and Digital Fusion believe that the proposed merger will allow Kratos and Digital Fusion to be better positioned to compete in the rapidly evolving defense and security solutions industry.
PROPOSED MERGERProposed Merger • July 29th, 2022
Caladrius Biosciences, Inc. (‘‘Caladrius’’) and Cend Therapeutics, Inc. (‘‘Cend’’) have entered into an Agreement and Plan of Merger and Reorganization (the ‘‘Merger Agreement’’) pursuant to which a wholly owned subsidiary of Caladrius will merge with and into Cend, with Cend surviving as a wholly owned subsidiary of Caladrius (the ‘‘Merger’’).
PROPOSED MERGER—YOUR VOTE IS VERY IMPORTANTProposed Merger • June 22nd, 2011
Kratos Defense & Security Solutions, Inc. (‘‘Kratos’’) and Integral Systems, Inc. (‘‘Integral Systems’’) entered into a merger agreement on May 15, 2011, pursuant to which a wholly-owned subsidiary of Kratos will merge with and into Integral Systems and Integral Systems will become a wholly-owned subsidiary of Kratos upon completion of the merger. The board of directors of each of Kratos and Integral Systems has unanimously approved the merger agreement and the merger.
PROPOSED MERGERProposed Merger • February 11th, 2021
Seneca Biopharma, Inc. (“Seneca”) and Leading BioSciences, Inc. (“LBS”) have entered into an Agreement and Plan of Merger (the “Merger Agreement”), pursuant to which a wholly-owned subsidiary of Seneca will merge with and into LBS, with LBS surviving as a wholly-owned subsidiary of Seneca (the “Merger”). The Merger will result in a clinical-stage biopharmaceutical company focused on advancing LBS’s clinical program and developing a therapeutic to combat the interruption of gastrointestinal function following major surgery for which there is currently a significant unmet need for safe and effective therapies.
PROPOSED MERGERProposed Merger • April 13th, 2021
Millendo Therapeutics, Inc., a Delaware corporation, or Millendo, and Tempest Therapeutics, Inc., a Delaware corporation, or Tempest, entered into an Agreement and Plan of Merger, or the Merger Agreement, on March 29, 2021, pursuant to which a direct, wholly owned subsidiary of Millendo, Mars Merger Corp., or Merger Sub, will merge with and into Tempest, with Tempest surviving as a wholly owned subsidiary of Millendo, and the surviving corporation of the merger, which transaction is referred to herein as the merger. The surviving corporation following the merger is referred to herein as the combined company.
As previously announced, LogMeIn, Inc., which we refer to as LMI, and Citrix Systems, Inc., which we refer to as Citrix, have entered into an agreement and plan of merger, dated as of July 26, 2016, as may be amended from time to time, which we refer...Proposed Merger • December 16th, 2016 • GetGo, Inc. • Services-prepackaged software • Delaware
BACKGROUNDProposed Merger • March 28th, 2000 • Channelpoint Inc
PROPOSED MERGERProposed Merger • July 18th, 2020
Aduro Biotech, Inc., a Delaware corporation, or Aduro, and Chinook Therapeutics U.S., Inc., a Delaware corporation, or Chinook, entered into an Agreement and Plan of Merger and Reorganization, or the Merger Agreement, on June 1, 2020, pursuant to which a direct, wholly owned subsidiary of Aduro, Aspire Merger Sub, Inc., or Merger Sub, will merge with and into Chinook, with Chinook surviving as a wholly owned subsidiary of Aduro, and the surviving corporation of the merger, which transaction is referred to herein as the merger. The surviving corporation following the merger is referred to herein as the combined company.
